assessing the percent of necrosis after neoadjuvant chemotherapy with 24hr infusional cisplatin/3 days doxorubicin intermittent with ifosfamide-doxorubicin for osteosarcoma.

نویسندگان

mozhgan aalam samimi assistant professor, minimally invasive surgery research center, iran university of medical science, tehran, iran.

nooshin mirkheshti medical doctor, east sage research corporation, isfahan science and technology town, isfahan, iran.

abdolreza pazouki assistant professor, minimally invasive surgery research center, iran university of medical science, tehran, iran.

چکیده

introduction: osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. yet, the toxicity of chemotherapy regimens including mtx can be life threatening. therefore; we tried another chemotherapy regimen for these patients. method and materials: we investigated 15 patients aged 15 to 40 years old and used continuous infusion of cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. percent of necrosis and toxicities was recorded for each patient. results: out of 15 patients investigated, 13 were males and 2 females. tumor necrosis≥ 90% (defined as good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four. conclusion: the above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens including high dose of mtx with reduced toxicity and less nursing cares and laboratory tests. of course small sample size limits extension of our result to all patients but trying this regimen is recommended in more patients to see more reliable results.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma

INTRODUCTION Osteosarcoma is the most common primary bone tumor in children and young adults and appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these patients. METHOD AND MATERIALS We investigated 15 patients aged 15 to 40 years old a...

متن کامل

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

The present study investigated the safety and efficacy of neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcoma in adult and older patients. A total of 18 consecutive patients with bone sarcoma (American Joint Committee on Cancer stage II in 14 patients and stage IV in four) treated with neoadjuvant and adjuvant chemotherapy at Nagoya Musculoskeletal Oncology Gr...

متن کامل

Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer

PURPOSE This study was performed to compare the therapeutic efficacy and toxicity of doxorubicin plus docetaxel neoadjuvant chemotherapy (NC) with doxorubicin plus vinorelbine NC. METHODS Fifty-three patients underwent 4 cycles of NC consisted of intravenous injection of doxorubicin (50 mg/m(2)) plus docetaxel (75 mg/m(2)) administered every 3 weeks (AD), while 49 patients underwent 4 cycles ...

متن کامل

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.

PURPOSE We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity. PATIENTS AND METHODS Patients age ≤ 40 years randomly received regimens with the same cumulative doses of drugs (ADM 420 mg/m(2), MTX 120 g/m(2), CDP 600 mg/m(2), and IFO 30 g/m(2))...

متن کامل

Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.

BACKGROUND We assessed the efficacy and toxicity of ifosfamide and doxorubicin combination chemotherapy (CT) regimen retrospectively in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. METHODS A total of thirty patients who had received cisplatin based chemotherapy/chemoradiotherapy as a primary treatment receive...

متن کامل

odeling Associated with Doxorubicin Chemotherapy

Downlo orubicin is a highly effective cancer treatment whose use is severely limited by dose-dependent cardiity. It is well established that doxorubicin increases reactive oxygen species (ROS) production. In this we investigated contributions to doxorubicin cardiotoxicity from Nox2 NADPH oxidase, an important ource in cardiac cells, which is known to modulate several key processes underlying th...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۸، شماره ۱، صفحات ۵-۸

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023